Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictors of Exposure Success in Public Speaking Anxiety

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02163148
Recruitment Status : Completed
First Posted : June 13, 2014
Last Update Posted : May 27, 2015
Sponsor:
Information provided by (Responsible Party):
Tali Manber Ball, University of California, San Diego

Brief Summary:
Anxiety disorders are common and impairing. Although exposure therapy is one of the most effective treatments for anxiety, some individuals do not fully respond to treatment, and these individual differences are not well understood. Exposure therapy involves repeated, deliberate, safe engagement with a feared stimulus without the feared outcome occurring. This treatment is thought to work through a type of emotional learning called fear extinction. This study aims to look at links between fear extinction learning and exposure success, with the overall goal of better understanding who is likely to respond best to exposure therapy and why.

Condition or disease Intervention/treatment
Performance Anxiety Behavioral: Massed speech exposure session

Layout table for study information
Study Type : Observational
Actual Enrollment : 24 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Predictors of Exposure Success in Public Speaking Anxiety
Study Start Date : May 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Group/Cohort Intervention/treatment
Public Speaking Anxiety
Intervention to be administered: One speech exposure session.
Behavioral: Massed speech exposure session
One session consisting of 4 speech exposures, each 5 minutes long.




Primary Outcome Measures :
  1. Change in peak Subjective Unit of Distress (SUDS) rating from first to fourth (last) exposure [ Time Frame: 90 minutes ]
    Participants will complete 4 exposures during one 90 minute session. Change in the peak ratings on the final exposure relative to the first exposure will be the outcome measure.


Secondary Outcome Measures :
  1. Change from baseline on the Liebowitz Social Anxiety Scale (LSAS) at 2 weeks [ Time Frame: Baseline, week 2 ]
  2. Change from baseline on the Personal Report of Confidence as a Speaker (PRCS) at 2 weeks [ Time Frame: Baseline, week 2 ]

Other Outcome Measures:
  1. Change from baseline on the Sheehan Disability Scale (SDS) at week 2 [ Time Frame: Baseline, week 2 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community sample
Criteria

Inclusion Criteria:

  • Score of at least 20 on the PRCS
  • Age 18-55
  • English fluency

Exclusion Criteria:

  • Psychotropic medication use in the past 4 weeks
  • Past experience with exposure based therapy
  • History of bipolar disorder, psychotic disorder, or substance dependence
  • Current major depressive disorder of greater than moderate severity (defined as a score on the 9 item Patient Health Questionnaire of greater than 14)
  • Clinically significant suicidal or homicidal ideation
  • Non-removable ferrous metal
  • Current significant neurological conditions
  • History of loss of consciousness greater than 5 minutes duration
  • Pregnant
  • Claustrophobic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02163148


Locations
Layout table for location information
United States, California
UCSD Psychiatry Research
San Diego, California, United States, 92037
Sponsors and Collaborators
University of California, San Diego
Investigators
Layout table for investigator information
Principal Investigator: Tali M Ball, MA UCSD
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tali Manber Ball, Doctoral Candidate, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02163148    
Other Study ID Numbers: UCSDIRB-130313
First Posted: June 13, 2014    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Mental Disorders